133 related articles for article (PubMed ID: 27974685)
1. Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma.
Liang JH; Ding CY; Gale RP; Wang L; Xu J; Qu XY; Fan L; Li TL; Li JY; Xu W
Oncotarget; 2017 Jan; 8(1):1737-1743. PubMed ID: 27974685
[TBL] [Abstract][Full Text] [Related]
2. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
[TBL] [Abstract][Full Text] [Related]
4. [Pretreatment evaluation of
Peng P; Wu N; Tao XL; Liu Y; Lyu L; Cheng X
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):370-376. PubMed ID: 35448927
[No Abstract] [Full Text] [Related]
5. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
6. Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma.
Xia X; Wang Y; Yuan J; Sun W; Jiang J; Liu C; Zhang Q; Ma X
Medicine (Baltimore); 2020 Sep; 99(37):e22143. PubMed ID: 32925768
[TBL] [Abstract][Full Text] [Related]
7. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
[TBL] [Abstract][Full Text] [Related]
9. Utility of baseline, interim and end-of-treatment
Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
11. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
12. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma.
Li XF; Fu Q; Dong YW; Liu JJ; Song XY; Dai D; Zuo C; Xu WG
World J Gastroenterol; 2016 Sep; 22(34):7787-96. PubMed ID: 27678362
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.
Huang H; Xiao F; Han X; Zhong L; Zhong H; Xu L; Zhu J; Ni B; Liu J; Fang Y; Zhang M; Shen L; Wang T; Liu J; Shi Y; Chen Y; Zheng L; Liu Q; Chen F; Wang J
Nucl Med Commun; 2016 Jul; 37(7):689-98. PubMed ID: 27244584
[TBL] [Abstract][Full Text] [Related]
14.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma.
Chen X; Zhao S; Wang H; Fu C; Tian R; Zou L
Quant Imaging Med Surg; 2021 Apr; 11(4):1220-1233. PubMed ID: 33816162
[TBL] [Abstract][Full Text] [Related]
17. The Incremental Prognostic Value of Baseline
Wang H; Yu W; Wu T; Xue Y; Zhang D; Xu H
Biomed Res Int; 2020; 2020():4502489. PubMed ID: 32596312
[TBL] [Abstract][Full Text] [Related]
18. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
Jo JE; Kim JY; Lee SH; Kim S; Kang T
Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
[TBL] [Abstract][Full Text] [Related]
20. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
